Biotech RadarJobs updated

COMPANY

Kallyope

HQ: New York, NY source · kallyope.com ↗

Also known as: TriGemX Bio (new name, Oct 1, 2026) · source

Clinical Phase 3

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Migraine Obesity Acute Migraine Type 2 Diabetes Mellitus (T2DM) Type 2 Diabetes Mellitus in Obese Elismetrep Elismetrep (K-304) K-757

9Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $94M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Trial start Phase 3: A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine source ↗
  2. Raise Undisclosed round · $94M source ↗
  3. Trial start Phase 3: A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine source ↗
  4. Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine source ↗
  5. Trial start Phase 2: A Study of K-645 in the Treatment of Multiple Migraine Attacks source ↗
  6. Trial start II: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine source ↗
  7. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes source ↗
  8. Trial start Phase 2: A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833 source ↗
  9. Trial start Phase 1: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes source ↗
  10. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT07816367A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 3RecruitingOct 2, 20262027-10 (estimated)
NCT06848075A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of MigraineIICompletedMar 11, 2025Aug 4, 2025 (actual)
NCT07674654A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 3RecruitingAug 3, 20262028-06 (estimated)
NCT07645924A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 3RecruitingJul 1, 20262027-02 (estimated)
NCT07116499A Study of K-645 in the Treatment of Multiple Migraine AttacksPhase 2TerminatedAug 12, 2025Nov 7, 2025 (actual)
NCT06019559A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833Phase 2CompletedSep 15, 2023Feb 7, 2024 (actual)
NCT05900531A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese VolunteersPhase 1CompletedSep 21, 2022May 3, 2023 (actual)
NCT06305351A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesPhase 1CompletedDec 7, 2023May 15, 2024 (actual)
NCT05890950A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesPhase 1CompletedMar 13, 2023Jul 12, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback